1644
clinical study

Predictive values of AI-based triage model in suboptimal CT pulmonary angiography

Materials & Methods

In an IRB approved, retrospective study we identified 104 consecutive, suboptimal CTPA which were deemed as suboptimal for PE evaluation in radiology reports due to motion, artifacts and/or inadequate contrast enhancement. We enriched this dataset, with additional 226 optimal CTPA (over same timeframe as suboptimal CTPA) with and without PE. Two thoracic radiologists (ground truth) independently reviewed all 330 CTPA for adequacy (to assess PE down to distal segmental level), reason for suboptimal CTPA (artifacts or poor contrast enhancement), as well as for presence and location of PE. CT values (HU) were measured in the main pulmonary artery. Same attributes were assessed in 80 patients who had repeat or follow-up CTPA following suboptimal CTPA. All CTPA were processed with the PE-AI (Aidoc).

Results

Among 104 suboptimal CTPA (mean age ± standard deviation 56 ± 15 years), 18/104 (17%) were misclassified as suboptimal for PE evaluation in their radiology reports but relabeled as optimal on ground truth evaluation. Of 226 optimal CTPA, 47 (21%) were reclassified as suboptimal CTPA. PEs were present in 97/330 CTPA. PE-AI had similar performance on suboptimal CTPA (sensitivity 100%; specificity 89%; AUC 0.89, 95% CI 0.80–0.98) and optimal CTPA (sensitivity 96%; specificity 92%; AUC 0.87, 95% CI 0.81–0.93).

Conclusions

Suboptimal CTPA examinations do not impair the performance of PE-AI triage model; AI retains clinically meaningful sensitivity and high specificity regardless of diagnostic quality.

Explore the Latest AI Insights, Trends and Research

Amalia Schreier

<p>Amalia Schreier serves as the Senior Vice President of Regulatory Affairs and Legal at Aidoc, guiding our company and product’s regulatory strategies and ensuring alignment with AI-focused medical device compliance requirements. Since her tenure began, she has streamlined our FDA clearance processes, emphasizing a meticulous approach that underscores our commitment to product and clinical quality.</p> <p>With a solid foundation from her legal background and leadership role in AI startup regulatory departments, Schreier brings invaluable insights and expertise to our regulatory framework. Prior to her tech world experience, she worked as a human-rights lawyer and legal policy scholar, with a BA and LLM in law from the Hebrew University of Jerusalem.</p>

Deepak Srikant

<p>Deepak Srikant is a global marketing executive with over 20 years of experience, specializing in the commercialization of medical devices and digital health solutions. He has a proven track record in driving growth, having led successful go-to-market strategies, product launches and market expansions across the U.S. and EMEA.</p> <p>Srikant’s expertise extends to upstream and downstream marketing, professional education and sales enablement. His leadership at companies such as Silk Road Medical (acquired by Boston Scientific) and Aptus Endosystems (acquired by Medtronic) has consistently resulted in revenue growth, enhanced customer retention and successful product adoption.</p> <p>Srikant holds an MBA from the Yale School of Management and a bachelor’s degree in mechanical engineering from Rensselaer Polytechnic Institute. Currently, he leads product marketing for Aidoc’s cardiovascular service line.</p>

Laci Costa

<p>Laci Costa is the Director of Neurovascular Product Marketing at Aidoc. She leads marketing and commercial strategy for the neuro AI portfolio of products. She has 16 years of experience working in the medical device and healthcare industry, with over 12 years dedicated to neurovascular solutions.</p> <p>Costa’s known for her expertise in the neurovascular industry, go-to-market experience with new technologies and upstream and downstream product marketing leadership. She’s held various leadership positions in product marketing, clinical education and professional affairs spanning across start-up organizations to large publicly traded companies.</p> <p>Costa holds a bachelor’s degree in psychology from the University of Oklahoma and an MBA from USC Marshall School of Business.</p>